Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines

Journal of Women's Health

Volumn 23, Issue 4, 2014, Pages 310-317

  Coffee, Andrea L ^a   Sulak, Patricia J ^a   Hill, Alexandria J ^a   Hansen, Darci J ^a   Kuehl, Thomas J ^b   Clark, Jeffrey W ^b  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; FROVATRIPTAN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MENSTRUAL MIGRAINE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CARBAZOLES; CONTRACEPTIVES, ORAL, COMBINED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; MENSTRUAL CYCLE; MENSTRUATION; MIGRAINE DISORDERS; SEROTONIN RECEPTOR AGONISTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRYPTAMINES; YOUNG ADULT;

EID: 84898017596     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2013.4485     Document Type: Article

References (21)

1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-349.
2. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia 2004;24:9-160.
3. Brandes JL. The influence of estrogen on migraine: a systematic review. JAMA 2006;295:1824-1830.
4. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-266.
5. Sulak P, Willis S, Kuehl T, Coffee A, Clark J. Headaches and oral contraceptives: Impact of eliminating the standard 7-day placebo interval. Headache. 2007;47:27-37.
6. Sulak PJ, Carl J, Gopalakrishnan I, Coffee A, Kuehl TJ. Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding. Contraception. 2004;70:281-287.
7. Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol 2006;195:935-941.
8. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology 2006;67: 2159-2163.
9. Guidotti M, Mauri M, Barillà C, Guidotti F, Belloni C. Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine. J Heachache Pain 2007;8:283-288.
10. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004;63:261-269.
11. Allais G, Bussone G, Airola G, et al. Oral contraceptiveinduced menstrual migraine. Clinical aspects and response to frovatriptan. Neurol Sci 2008;29:S186-S190.
12. Coffee AL, Kuehl TJ, Sulak PJ. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives. Pharmacotherapy 2008;28:576-583.
13. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the migraine disability assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine suffers. Pain 2000;88:41-52.
14. Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007;75:444-449.
15. Coffee AL, Kuehl TJ,Willis S, Sulak PJ. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006;195:1311-1319.
16. Hatcher RA, Trussell J, Nelson A, Cates Jr W, Stewart F, Kowal D (eds). Contraceptive technology. New York, NY: Ardent Media, Inc., 2007, p. 477.
17. Géraud G, Keywood C, Senard JM. Migraine headache recurrence: Relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003; 43:376-388.
18. MacGregor EA, Brandes JL, Silberstein S, et al. Safety and tolerability of short-term preventive frovatriptan: a combined analysis. Headache 2009;49:1298-1314.
19. Brandes JL, Poole AC, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2009;29:1133-1148.
20. Macgregor EA, Pawsey ST, Campbell JC, Hu X. Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies. Gend Med 2010;7:88-108.
21. Mannix LK, Savani N, Landy S, et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 2007; 47:1037-1049.